<DOC>
	<DOCNO>NCT01824069</DOCNO>
	<brief_summary>It demonstrate feasibility , safety effectiveness mesenchymal stem cell derive lipoaspirate treat various pathology fistula . With project address study population critical ischemia lower limb without possibility revascularization , either technical criterion ( intervention possible compensate lack irrigation limb ) criterion risk / benefit ( intolerable surgical risk type intervention require ) . It almost always elderly patient multiple comorbidities high surgical risk lower limb ischemia critical degree , high probability major amputation short term immediate . Hypothesis : mesenchymal stem cell obtain lipoaspirate expand `` ex vivo '' , capable promote angiogenesis de novo improve critical limb ischemia lower nonrevascularizable safe manner</brief_summary>
	<brief_title>Treatment CLI Nonrevascularizable Lower Limb With Cell Therapy</brief_title>
	<detailed_description>The primary endpoint safety feasibility study do patient receive treatment 12 month implantation . It define process safe development monitor trial adverse event may relate propose therapy trial . All adverse event collected time monitor clinical evaluation . The main objective assess cumulative incidence adverse effect attribute study therapy . Secondary endpoint : As part evaluation quality life patient clinical evaluation treatment 6 , 9 12 month implantation Test SF-12 , magnetic resonance angiography , tissue oximetry record ankle-brachial index</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>1 . Informed Consent . 2 . &gt; 18 year . 3 . Chronic arterial ischemia grade IVV Rutherford affect least one limb . 4 . Arterial occlusion direct flow distal femoropopliteal level . 5 . No option surgical endovascular revascularization . 6 . Life expectancy exceed two year . 7 . High probability need major amputation 6 month ( CLI nonrevascularizable ) . 8 . Negative pregnancy test applicable . 1 . Background hematologic neoplasia unresolved . 2 . Hipertensi√≥n uncontrolled blood ( &gt; 180/110 ) . 3 . Severe heart Insuficiencia ( New York Heart Association [ NYHA ] IV ) ejection fraction &lt; 30 % . 4 . Malignant ventricular , Arritmias . 5 . Trombosis deep vein past three month . 6. active infection . 7 . Infarto infarction stroke previous three month . 8 . Medical psychiatric illness kind , opinion investigator , may reason exclusion study . 9 . Subjects congenital acquire immunodeficiency . Hepatitis B / C tuberculosis diagnose time inclusion , treponema . 10 . Major surgery severe trauma subject previous semester . 11 . Administration investigational drug present three month prior enrollment trial . 12 . Pulmonary heart disease , opinion investigator , unstable sufficiently serious dismiss patient study . 13 . Infants pregnant woman . 14 . Adult woman childbearing potential use effective contraception trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Critical Ischemia</keyword>
	<keyword>Amputation</keyword>
</DOC>